Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen - Wikidata - wikimedia - TriplyDB

Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen

Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen

http://www.wikidata.org/entity/Q34680647

about

New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu HIV-1 Genetic Variability and Clinical Implications High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease.Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.

P2860

Q27478093-CA575609-7A28-47BA-8739-46389B99B33C Q30352010-4FE4F4DF-8778-4C04-BE99-5985AE58FD8B Q35215399-906E4F34-98CC-41C9-9861-584D8BE8690C Q35260403-AF831AE0-D905-4834-90B3-7CAB940803D8 Q35260590-2B71C531-2494-4229-A988-DC243A0DAC88 Q35607740-8D09337E-224D-4850-8501-F7F62997C54B Q36077418-8C5D9A3D-AE2A-44C1-A61E-3BFF716EB275 Q36580646-C266543D-CC9D-434A-A435-A9379D3FC1B5 Q37268341-91B42FC6-227B-4FFD-B15C-1DD82C7511B8 Q37405816-C3601457-C063-45A1-B817-029A727141B9 Q39689383-8F2520C4-57D8-4A23-8772-386B03341370 Q39713096-4893E82D-BE52-4AC0-B8AD-CC0F19298654

P2860

Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen

http://www.wikidata.org/entity/Q34680647

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Impact of human immunodeficien ...... nelfinavir-containing regimen

@ast

Impact of human immunodeficien ...... nelfinavir-containing regimen

@en

Impact of human immunodeficien ...... nelfinavir-containing regimen

@nl

type

label

Impact of human immunodeficien ...... nelfinavir-containing regimen

@ast

Impact of human immunodeficien ...... nelfinavir-containing regimen

@en

Impact of human immunodeficien ...... nelfinavir-containing regimen

@nl

prefLabel

Impact of human immunodeficien ...... nelfinavir-containing regimen

@ast

Impact of human immunodeficien ...... nelfinavir-containing regimen

@en

Impact of human immunodeficien ...... nelfinavir-containing regimen

@nl

P1433

Q34680647-9374B085-D92B-44A4-AFCA-099F1CEBAA19

P1476

Q34680647-D191F03C-6007-4C5F-9E83-69105EBE2A7E

P2093

Q34680647-06A7088F-EEBA-43C3-B073-8A91BCC5DB78

Q34680647-2C636E60-CDBB-4E71-9B41-0A5F62AAA681

Q34680647-376876B3-A8C1-4D8D-8669-798393485C1E

Q34680647-4D2559AD-4186-4BAF-97B2-3673961C0CEE

Q34680647-53917480-7D0B-4FF4-8AD9-70687BA70624

Q34680647-5C43AD95-6BDB-4390-9465-76E487A57403

Q34680647-8561FCA9-65A2-4B1E-97C7-3743F1613B84

Q34680647-A4C94891-8F62-4EF8-BBCD-3A68909D1A6A

Q34680647-AFDCF94B-1D2E-4CE6-B613-AF48C75D866A

Q34680647-B428EA83-0FB7-4FAB-BB12-12BE44F4735D

P2860

Q34680647-079612E3-D9D6-484A-9FC1-1EC8959523F2

Q34680647-129ADED7-BD7C-4E03-8810-12F9BDF5EB93

Q34680647-272446BA-F1EC-463C-A338-1BFD3B151DA2

Q34680647-2C2B8682-6F9F-407B-AC86-5B362A394C1E

Q34680647-326A3087-6ED1-4EC9-8C8B-F88E79D169A8

Q34680647-36E42EA3-525F-407F-B6BD-FEB2B90F0103

Q34680647-3CD40C3B-AC22-4005-B512-AC2242BE3F30

Q34680647-409F5593-ED07-4A0C-9627-041D71CE6F83

Q34680647-52B27651-9EF3-46DB-9120-8CACA5B586A1

Q34680647-5849B553-C74A-4C3A-943C-D307D7A46E87

P304

Q34680647-D2F077A4-F697-484C-ABC7-D61DC256B3D1

P31

Q34680647-2CFD699C-8857-49D7-A633-FAC88232133D

P356

Q34680647-C07C4827-ED85-457A-AF71-0370A361C25A

P407

Q34680647-9A8A7B12-7758-4A6C-84D2-1777720B12BD

P433

Q34680647-AAA420C1-70DF-4CF0-B282-B572435A8683

P478

Q34680647-40ECABCA-71CB-4F4A-BAE8-35CE5E970DE4

P50

Q34680647-CEA34D85-36CB-4BC4-84E3-CF1E5D99AD37

Q34680647-E3318B98-E42A-48AB-8870-4E93C0BB7E5F

P577

Q34680647-1CBB8E3E-E435-4E58-AC2B-12376491A9B8

P698

Q34680647-7674B584-B9CF-41D8-A5B2-FB80BA1CAE23

P921

Q34680647-ECCFDF0B-90B2-422D-BE98-48BD48EC349F

P932

Q34680647-9266C121-0F1B-4557-9FDC-C53BCB1D60D2

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Impact of human immunodeficien ...... nelfinavir-containing regimen

@en

P2093

Ava Avalos

http://www.w3.org/2001/XMLSchema#string

Bluma Brenner

http://www.w3.org/2001/XMLSchema#string

Daniella Moisi

http://www.w3.org/2001/XMLSchema#string

Florence Doualla-Bell

http://www.w3.org/2001/XMLSchema#string

Howard Moffat

http://www.w3.org/2001/XMLSchema#string

Ibou Thior

http://www.w3.org/2001/XMLSchema#string

Madisa Mine

http://www.w3.org/2001/XMLSchema#string

Mark A Wainberg

http://www.w3.org/2001/XMLSchema#string

Maureen Oliveira

http://www.w3.org/2001/XMLSchema#string

Ndwapi Ndwapi

http://www.w3.org/2001/XMLSchema#string

P2860

Estimated Global Distribution and Regional Spread of HIV-1 Genetic Subtypes in the Year 2000

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.

Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precur

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

The impact of HIV-1 subtype on the clinical response on HAART.

In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.

P304

2210-2213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01447-05

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Simani Gaseitsiwe

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16723586

http://www.w3.org/2001/XMLSchema#string

P921

P932

1479146

http://www.w3.org/2001/XMLSchema#string